Oxford University Hospitals NHS Foundation Trust

PRMA Welcomes Esteemed Surgeon Dr. Anton Fries as the 9th Addition to its Surgical Team

Retrieved on: 
목요일, 9월 14, 2023
Plastic surgery, Lymphedema, University, University of Texas Health Science Center at San Antonio, University of Cambridge, UT Health San Antonio Cancer Center, Cosmetics, Research, Medicine, Oxford University Hospitals NHS Foundation Trust, Royal Navy, Surgeon, Patient, SAN, Plastic, Microsurgery, Faculty, Commander of the Navy (Sri Lanka), Family, Cleft lip and cleft palate, Dentistry, Nursing

SAN ANTONIO, Sept. 14, 2023 /PRNewswire-PRWeb/ -- PRMA, a leader in advanced plastic and reconstructive surgery, is proud to announce the appointment of Dr. Anton Fries as its newest surgeon. With an impressive medical journey that spans the globe and encompasses a wealth of expertise, Dr. Fries brings a unique set of skills and experiences to the PRMA team.

Key Points: 
  • PRMA, a renowned leader in advanced plastic and reconstructive surgery, proudly welcomes Dr. Anton Fries as its latest surgeon.
  • The addition of Dr. Fries to PRMA enhances their capacity to offer cutting-edge procedures, serving patients not only in San Antonio but across Texas and beyond.
  • Dr. Anton Fries joining the PRMA surgical team underscores the organization's commitment to providing the utmost expertise and care.
  • With Dr. Anton Fries joining the PRMA surgical team, the organization reinforces its commitment to providing the highest level of expertise and care to its patients.

Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting

Retrieved on: 
금요일, 8월 11, 2023
Diamond, CGC, Court of general sessions, University, Augusta University, Workflow, Genomics, NGS, University of Washington, Cancer, Bone marrow, Research, Oxford University Hospitals NHS Foundation Trust, International Cancer Genome Consortium, MD Anderson Cancer Center, Chemistry, SAN, Annual general meeting, California Hospital Medical Center, Children's Hospital Los Angeles, Hospital, Cytogenetics, Leukemia, Panel discussion, Nationwide, OGM, Very important person, Medical device, Vaccine, Medical imaging

CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research.

Key Points: 
  • CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research.
  • During this interactive session, experts will discuss their experience implementing OGM, key applications, and potential implications for future clinical research and medical guidelines.
  • Thirteen separate scientific presentations highlighting OGM as a novel technique in cancer research will be given at the conference.
  • In addition, three posters featuring results from OGM applications in cytogenetics and cancer research will be presented at the conference.

Brainomix AI Technology Improves Access to Stroke Treatment across the NHS

Retrieved on: 
화요일, 8월 8, 2023
Communication, CT, A&E, Oxford, Disability, Stroke, Innovation, Brain, Oxford University Hospitals NHS Foundation Trust, OXFORD, Thrombectomy, MRI, Hospital, Patient, NHS Long Term Plan, Artificial intelligence, ISDN, AI, NHS, Oxford University Press, Software, Pharmaceutical industry, Medical imaging, Nursing, Health, Fellow of the Academy of Medical Sciences

Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.

Key Points: 
  • Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.
  • After Brainomix secured the NHS AI in Health and Care Award in 2020, the Oxford AHSN supported the spread and adoption of e-Stroke through participating Integrated Stroke Delivery Networks (ISDNs).
  • Feedback from NHS colleagues reported that the software is helping them to deliver a more efficient and effective stroke services for their patients.
  • We look forward to seeing more results as they come out, building on the largest real-world and independent evaluation of a stroke AI imaging platform."

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
수요일, 7월 12, 2023
Inflammation, CT, Plaque, NHS England, National Health Service, Cardiovascular disease, University Hospitals Cleveland Medical Center, CAD, Liverpool Heart and Chest Hospital NHS Foundation Trust, FAI, CCTA, Atherosclerosis, Milton Keynes University Hospital, Hospital, Patient, Oxford University Hospitals NHS Foundation Trust, Risk, Royal Wolverhampton NHS Trust, University Hospitals of Leicester NHS Trust, Algorithm, Artificial intelligence, NHS, Coronary artery disease, NICE, Pharmaceutical industry, Medical imaging, EU

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
수요일, 7월 12, 2023
Inflammation, CT, Plaque, NHS England, National Health Service, Cardiovascular disease, University Hospitals Cleveland Medical Center, CAD, Liverpool Heart and Chest Hospital NHS Foundation Trust, FAI, CCTA, Atherosclerosis, Milton Keynes University Hospital, Hospital, Patient, Oxford University Hospitals NHS Foundation Trust, Risk, Royal Wolverhampton NHS Trust, University Hospitals of Leicester NHS Trust, Algorithm, Artificial intelligence, NHS, Coronary artery disease, NICE, Pharmaceutical industry, Medical imaging, EU

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Acutus Medical to Showcase Innovative Cardiac Mapping and Ablation Technologies at HRS 2023

Retrieved on: 
월요일, 5월 15, 2023
HRS, AFIB, Trust, Research, Oxford University Hospitals NHS Foundation Trust, Marketing, South Tees Hospitals NHS Foundation Trust, Cardiac electrophysiology, Patient, Physician, Electrophysiology, Map, The Retreat, Principal, AF, Arrhythmia, Pharmaceutical industry, Medical device

As an exhibitor at HRS, Acutus Medical will showcase its latest groundbreaking electrophysiology systems and technologies, including AcQMap®, the industry's only whole-chamber, single-beat, non-contact mapping system.

Key Points: 
  • As an exhibitor at HRS, Acutus Medical will showcase its latest groundbreaking electrophysiology systems and technologies, including AcQMap®, the industry's only whole-chamber, single-beat, non-contact mapping system.
  • “We are pleased to join HRS ’23 to offer the industry an opportunity to engage directly with our state-of-the-art cardiac mapping and ablation therapy technologies, as well as meet with many of our key physician partners,” said David Roman, President & CEO of Acutus Medical.
  • In addition to Dr. Betts’ presentation, Acutus Medical is hosting a wide variety of events, including a range of peer-to-peer presentations from leading cardiac electrophysiologists and current Acutus users, live demonstrations and case reviews, and physician-led discussions.
  • “As a pioneer in the field of electrophysiology, Acutus Medical delivers cutting-edge tools that provide critical information conventional mapping systems cannot, which helps physicians deliver personalized therapy for atrial arrhythmias,” said Shibaji Shome, Ph.D., Vice President of Marketing at Acutus Medical.

RECOVER AF Study Reports 91% of First Redo Patients Achieved Freedom from AF at One Year After AcQMap-guided Ablation Therapy

Retrieved on: 
목요일, 4월 20, 2023
FRCP, Freedom, EP Europace, PCP, PVI, Atrial fibrillation, AFIB, Oxford University Hospitals NHS Foundation Trust, PVS, Catheter, Patient, Map, The Retreat, AF, Arrhythmia, Nursing, Medical imaging, Bachelor of Medicine, Bachelor of Surgery, MD

76% of patients undergoing retreatment with AcQMap-guided ablations experienced freedom from AF at one year.

Key Points: 
  • 76% of patients undergoing retreatment with AcQMap-guided ablations experienced freedom from AF at one year.
  • Furthermore, freedom from AF was particularly high for patients who had only PVI before enrollment compared to those who had PVI plus additional non-PV ablations (91% vs. 63%, p
  • The outcomes provide clear evidence that advanced, patient-specific mapping with the AcQMap system leads to superior outcomes over empirical approaches, especially when used earlier in the patient’s treatment pathway.
  • “The RECOVER AF study’s findings help advance our strategy to become the system-of-choice for EPs treating complex arrhythmias, including for patients undergoing treatment for persistent AF,” said David Roman, President & CEO of Acutus Medical.

Ibex Secures PathLAKE Contracts to Roll Out AI-based Cancer Diagnostics to UK Hospitals

Retrieved on: 
화요일, 3월 7, 2023
Trust, Hospital, Trust law, Prostate cancer, Diagnosis, Wales, Addenbrooke's Hospital, Artificial intelligence, Consultant, Innovate UK, Breast, Prostate, Woman, TEL, Nottingham University Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer, Laboratory, University Hospitals Coventry and Warwickshire NHS Trust, Innovation, Pathology, University, AI, Oxford University Hospitals NHS Foundation Trust, Marie Cassidy, Digital pathology, Addenbrooke, Megaproject, Medical device, Medical imaging, Ibex, NHS Wales

TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.

Key Points: 
  • TEL AVIV, Israel , March 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the receipt of multiple contract awards from the PathLAKE consortium  to provide Artificial Intelligence (AI) solutions to support cancer diagnosis at 25 NHS Trusts.
  • PathLAKE is a UK center of excellence consortium, founded by Innovate UK, that is delivering AI innovation in pathology across leading NHS Trusts and UK universities including Nottingham University Hospitals, University Hospitals Coventry & Warwickshire, and Oxford University Hospitals.
  • Cambridge University Hospitals is one of the Trusts to subsequently select Ibex to support its pathologists by augmenting diagnostic workflows with enhanced quality, accuracy and efficiency.
  • "We are extremely honored to be recognized by PathLAKE as the leading provider of AI solutions in pathology," said Richard Nicholson, Director of Sales, UK at Ibex.

BONESUPPORT's FDA Authorized CERAMENT® G to be featured at Orthopedic Trauma Association Annual Meeting (OTA)

Retrieved on: 
화요일, 10월 11, 2022
US Foods, Infection, Patient, Nasdaq, Technology, Foot, Fracture, Oxford University Hospitals NHS Foundation Trust, Trauma, CEO, Oxford, OTA, FDA, Pharmaceutical industry, MD

TAMPA, Fla., Oct. 11, 2022 /PRNewswire-PRWeb/ -- This week, BONESUPPORT, an emerging leader in orthobiologics, is attending the Orthopedic Trauma Association (OTA) annual meeting in Tampa, Florida. OTA is bringing together more than 400 accomplished orthopedic trauma surgeon presenters/moderators/authors who are sharing their expertise and experience, including delivering cutting-edge research findings and unique multi-national treatment perspectives. During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market authorization from the US Food and Drug Administration (FDA).

Key Points: 
  • TAMPA, Fla., Oct. 11, 2022 /PRNewswire-PRWeb/ -- This week, BONESUPPORT , an emerging leader in orthobiologics, is attending the Orthopedic Trauma Association (OTA) annual meeting in Tampa, Florida.
  • OTA is bringing together more than 400 accomplished orthopedic trauma surgeon presenters/moderators/authors who are sharing their expertise and experience, including delivering cutting-edge research findings and unique multi-national treatment perspectives.
  • Conducted at Oxford University Hospitals, the significant study followed 100 consecutive patients and found that with the use of CERAMENT G, 94% were infection free at a mean follow-up of six years.
  • It also showed a 3% fracture rate with no further pathologic fractures beyond the first year after surgery.

LiverMultiScan Shown to Be a Cost-Effective Alternative to Liver Biopsies for Monitoring Patients with Autoimmune Hepatitis

Retrieved on: 
수요일, 9월 21, 2022
Managed Care, Hospitals, Health, Medical Devices, Chronic liver disease, BMJ Open, Health, Precision medicine, Safety, NHS, 5-1-1, Oxford University Hospitals NHS Foundation Trust, Doctor of Philosophy, Autoimmune hepatitis, Woman, Magnetic resonance, McKay, Liver disease, MRI, Incidence, Patient, Genetics, Cancer, Physician, Technology, Systematic review, Fatty liver disease, Liver, Viral hepatitis, Diagnosis, Meta-analysis, AIH, Research, Hepatitis, Immune system, Innovation, Live Damage, Master of Science, Conditional sentence, Digestive Diseases and Sciences, Medical imaging, MBBS

Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.

Key Points: 
  • Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.
  • By eliminating risks and complications associated with liver biopsy, LiverMultiScan helps improve patient outcomes and experience.
  • Although necessary for diagnosis, liver biopsy is not sustainable for long-term monitoring of patients with AIH.
  • LiverMultiScan is a novel technology that addresses a critical unmet need for noninvasive techniques to diagnose and monitor patients with chronic liver diseases such as nonalcoholic steatohepatitis, autoimmune hepatitis, or viral hepatitis.